Hydroxy formamide derivatives and their use

Abstract

wherein R1, R2 and R3 are as defined herein, and methods of making and using the same, including use as inhibitors of BMP1, TLL1 and/or TLL2 and in treatment of diseases associated with BMP1, TLL1 and/or TLL2 activity.

What is claimed is: 
     
         1 . A method of treating a disease associated with BMP1, TLL1 and/or TLL2 activity in a human in need thereof comprising administering to said human a therapeutically effective amount of a compound of Formula (I): 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, 
         wherein: 
         R1 is selected from the group consisting of H, (C 1 -C 4 ) straight chain alkyl, and (C 1 -C 4 ) straight chain alkyl substituted with a hydroxy group; 
         R2 is selected from H, (C 1 -C 11 )alkyl, (C 1 -C 3 )alkyl-(C 3 -C 6 )cycloalkyl, (C 1 -C 3 )alkyl-phenyl, (C 1 -C 3 )alkyl-naphthyl and (C 1 -C 3 )alkyl-heterocyclyl, wherein heterocyclyl is a monocyclic ring having 5-6 ring atoms wherein 1-2 of the ring atoms are selected from nitrogen, oxygen and sulfur, and wherein said (C 1 -C 11 )alkyl, cycloalkyl, phenyl, naphthyl and heterocyclyl are optionally substituted with 1-2 groups independently selected from (C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxy, halo, and cyano; and 
         R3 is selected from:
 a) phenyl, optionally substituted with 1-3 groups independently selected from: 
 
         (C 1 -C 6 )alkyl, optionally substituted with 1-3 groups independently selected from: fluoro; —CO 2 H; —P(O)R f R g ; NR a R b  wherein R a  is selected from H and (C 1 -C 4 )alkyl and R b  is selected from (C 1 -C 4 )alkyl substituted with —CO 2 H or —P(O)R f R g , and —C(O)NR a R b  wherein R a  and R b  are independently selected from H and (C 1 -C 4 )alkyl, wherein the (C 1 -C 4 )alkyl is optionally substituted with 1-3 groups independently selected from hydroxy, —CO 2 H, —C(O)O(C 1 -C 4 )alkyl and —P(O)R f R g ; 
         cyclopropyl, optionally substituted with 1 —CO 2 H; 
         —C(O)NR a R b  wherein R a  and R b  are independently selected from H and (C 1 -C 4 )alkyl, wherein the (C 1 -C 4 )alkyl is optionally substituted with 1-3 groups independently selected from hydroxy, —CO 2 H, —C(O)O(C 1 -C 4 )alkyl, —P(O)R f R g , NR c R d  and N + R c R d R e ; 
         (C 1 -C 6 )alkoxy, optionally substituted with 1-3 substituents independently selected from halo, hydroxy, —CO 2 H, (C 3 -C 6 )cycloalkyl, —C(O)NH 2  and pyrrolidinyl; 
         (C 3 -C 6 )cycloalkoxy, optionally substituted with 1-3 substituents independently selected from halo, hydroxy, and —CO 2 H; 
         —NR a R b  wherein R a  and R b  are independently selected from H and (C 1 -C 4 )alkyl, wherein the (C 1 -C 4 )alkyl is optionally substituted with 1-3 groups independently selected from oxo and —CO 2 H; 
         —SR a  wherein R a  is selected from H and (C 1 -C 4 )alkyl; 
         —CO 2 H; —C(NOH)NH 2 ; cyano; —C(O)O(C 1 -C 4 )alkyl; —C(O)CO 2 H; —P(O)R f R g ; —OP(O)R f R g ; halo; hydroxy; nitro; —NHSO 2 (C 1 -C 2 )alkyl; —SO 3 H; —SO 2 (C 1 -C 2 )alkyl; —SO 2 NR c R d ; —SO 2 NHC(O)(C 1 -C 2 )alkyl; and —B(OH) 2 ;
 and 
 b) heteroaryl, optionally substituted with 1-2 groups independently selected from: 
 
         (C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxy, oxo, —CO 2 H, —P(O)R f R g , and —OP(O)R f R g ;
 wherein in each occurrence: R c , R d  and R e  are independently selected from H and (C 1 -C 2 )alkyl; and 
 R f  and R g  are independently selected from hydroxy, (C 1 -C 2 )alkyl and (C 1 -C 2 )alkoxy. 
 
       
     
     
         2 . The method according to  claim 1 , wherein the compound of Formula (I):
 R1 is selected from the group consisting of H, (C 1 -C 4 ) straight chain alkyl, and (C 1 -C 4 ) straight chain alkyl substituted with a hydroxy group;   R2 is selected from H, (C 1 -C 11 )alkyl, (C 1 -C 3 )alkyl-(C 3 -C 6 )cycloalkyl, (C 1 -C 3 )alkyl-phenyl, and (C 1 -C 3 )alkyl-heterocyclyl, wherein heterocyclyl is a monocyclic ring having 5-6 ring atoms wherein 1-2 of the ring atoms are selected from nitrogen, oxygen and sulfur, and wherein said (C 1 -C 11 )alkyl, cycloalkyl, phenyl, and heterocyclyl are optionally substituted with 1-2 groups independently selected from (C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxy, halo, and cyano; and   R3 is selected from:
 c) phenyl, optionally substituted with 1-3 groups independently selected from: 
   (C 1 -C 6 )alkyl, optionally substituted with 1-3 groups independently selected from: fluoro; —CO 2 H; —P(O)R f R g ; and —C(O)NR a R b  wherein R a  and R b  are independently selected from H and (C 1 -C 4 )alkyl, wherein the (C 1 -C 4 )alkyl is optionally substituted with 1-3 groups independently selected from hydroxy, —CO 2 H, —C(O)O(C 1 -C 4 )alkyl and —P(O)R f R g ;   cyclopropyl, optionally substituted with 1 —CO 2 H;   —C(O)NR a R b  wherein R a  and R b  are independently selected from H and (C 1 -C 4 )alkyl, wherein the (C 1 -C 4 )alkyl is optionally substituted with 1-3 groups independently selected from hydroxy, —CO 2 H, —C(O)O(C 1 -C 4 )alkyl, —P(O)R f R g , NR c R d  and N + R c R d R e ;   (C 1 -C 6 )alkoxy, optionally substituted with 1-3 substituents independently selected from halo, hydroxy, —CO 2 H, (C 3 -C 6 )cycloalkyl, and pyrrolidinyl;   (C 3 -C 6 )cycloalkoxy, optionally substituted with 1-3 substituents independently selected from halo, hydroxy, and —CO 2 H;   —NR a R b  wherein R a  and R b  are independently selected from H and (C 1 -C 4 )alkyl, wherein the (C 1 -C 4 )alkyl is optionally substituted with 1-3 groups independently selected from oxo and —CO 2 H;   —SR a  wherein R a  is selected from H and (C 1 -C 4 )alkyl;   —CO 2 H; —C(NOH)NH 2 ; cyano; —C(O)O(C 1 -C 4 )alkyl; —C(O)CO 2 H; —P(O)R f R g ; —OP(O)R f R g ; halo; hydroxy; nitro; —NHSO 2 (C 1 -C 2 )alkyl; —SO 3 H; —SO 2 (C 1 -C 2 )alkyl; —SO 2 NR c R d ; —SO 2 NHC(O)(C 1 -C 2 )alkyl; and —B(OH) 2 ;
 and 
 d) heteroaryl, optionally substituted with 1-2 groups independently selected from: 
   (C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxy, oxo, —CO 2 H, —P(O)R f R g , and —OP(O)R f R g ;
 wherein in each occurrence: R c , R d  and R e  are independently selected from H and (C 1 -C 2 )alkyl; and 
 R f  and R g  are independently selected from hydroxy, (C 1 -C 2 )alkyl and (C 1 -C 2 )alkoxy. 
   
     
     
         3 . The method according to  claim 1 , wherein the compound according to Formula (I) has the Formula (I)(a): 
       
         
           
           
               
               
           
         
       
     
     
         4 . The method according to  claim 1 , wherein the compound according to Formula (I) has the Formula (I)(b): 
       
         
           
           
               
               
           
         
       
     
     
         5 . The method according to  claim 1 , wherein R1 is H, methyl, ethyl or —CH 2 OH. 
     
     
         6 . The method according to  claim 1 , wherein R1 is methyl, ethyl or —CH 2 OH. 
     
     
         7 . The method according to  claim 1 , wherein R1 is ethyl. 
     
     
         8 . The method according to  claim 1 , wherein R2 is H or optionally substituted n-pentyl, 2-ethylbutyl, (cyclopentyl)methyl, benzyl, 2-phenylethyl, 3-phenylpropyl, or 2-naphthylethyl. 
     
     
         9 . The method according to  claim 1 , wherein R2 is n-pentyl. 
     
     
         10 . The method according to  claim 1 , wherein R1 and R2 have (R) stereochemistry. 
     
     
         11 . The method according to  claim 1 , wherein R3 is optionally substituted phenyl. 
     
     
         12 . The method according to  claim 11 , wherein R3 is disubstituted phenyl wherein the phenyl substituents are ethoxy in the 3-position and —P(O)(OH) 2 , —CO 2 H, —OCH 2 CO 2 H, or —C(O)NHCH(CO 2 H)(CH 2 CO 2 H) in the 4- or 5-position. 
     
     
         13 . The method according to  claim 11 , wherein R3 is phenyl substituted with 1-3 groups selected from: —OCH 3 , —OC 2 H 5 , —OC 3 H 7 , —OCH(CH 3 ) 2 , —OCF 3 , —OCHF 2 , —OCH 2 CF 3 , —OCH 2 CHF 2 , —OC 2 H 4 -pyrrolidine, —OCH 2 CO 2 H, —OCH 2 C(O)NH 2 , —CO 2 H, —CH 3 , cyclopropane-1-carboxylic acid, —CH 2 CO 2 H, —C(CH 3 ) 2 CO 2 H, —CH(CH 3 )CO 2 H, —CF 2  CO 2 H, —CH 2 C(O)NHCH(CO 2 H)(CH 2 CO 2 H), —CH 2 P(O)(OH) 2 , —CH 2 N(CH 3 )(CH 2 CO 2 H), —CH 2 NHCH 2 P(O)(OH) 2 , —C(NH 2 )(NOH), cyano, nitro, hydroxy, —SO 2 NH 2 , —SO 2 N(CH 3 ) 2 , —SO 2 NH(CH 3 ), —SO 2 CH 3 , —SO 2 NHC(O)C 2 H 5 , —SCH 3 , —SC 2 H 5 , —C(O)OCH 3 , —C(O)OC(CH 3 ) 3 , —C(O)NHCH 3 , —C(O)NH(C 2 H 4 NH 2 ), —C(O)NHC 2 H 4 N+(CH 3 ) 3 , —C(O)NHCH(CO 2 H)(CH 2 CO 2 H), —C(O)NHCH(CO 2 H)(C 2 H 4 CO 2 H), —C(O)NHCH 2 CO 2 H, —C(O)N(CH 2 CO 2 H) 2 , —C(O)NHCH 2 P(O)(OH) 2 , —C(O)NHC(CH 2 OH) 3 , fluoro, —NH 2 , —N(CH 3 ) 2 , —P(O)(CH 3 )(OC 2 H 5 ), —P(O)(OCH 3 ) 2 , —P(O)(CH 3 )(OH), —P(O)(OH)(OCH 3 ), and —P(O)(OH) 2 . 
     
     
         14 . The method according to  claim 13 , wherein R3 is phenyl substituted with 1-3 groups selected from: —OC 2 H 5 , hydroxy, —CO 2 H, —OCH 2 CO 2 H, —P(O)(OH) 2 , —C(O)NHCH(CO 2 H)(CH 2 CO 2 H) and —C(O)NHCH 2 P(O)(OH) 2 . 
     
     
         15 . The method according to  claim 1 , wherein R3 is optionally substituted pyridyl, pyridazinyl, pyrimidinyl, oxazolyl, tetrazolyl, pyrazolyl, indazolyl, or 1,1-dioxido-2,3-dihydrobenzo[d]isothiazolyl. 
     
     
         16 . The method according to  claim 1 , wherein the compound of Formula (I) is a compound of Formula (I)(b): 
       
         
           
           
               
               
           
         
         wherein: 
         R1 is H, methyl, ethyl or —CH 2 OH; 
         R2 is H or optionally substituted n-pentyl, 2-ethylbutyl, (cyclopentyl)methyl, benzyl, 2-phenylethyl, 3-phenylpropyl, or 2-naphthylethyl; and 
         R3 is selected from:
 a) phenyl, optionally substituted with 1-3 groups independently selected from: 
 
         (C 1 -C 6 )alkyl, optionally substituted with 1-3 groups independently selected from: fluoro; —CO 2 H; —P(O)R f R g ; NR a R b  wherein R a  is selected from H and (C 1 -C 4 )alkyl and R b  is selected from (C 1 -C 4 )alkyl substituted with —CO 2 H or —P(O)R f R g , and —C(O)NR a R b  wherein R a  and R b  are independently selected from H and (C 1 -C 4 )alkyl, wherein the (C 1 -C 4 )alkyl is optionally substituted with 1-3 groups independently selected from hydroxy, —CO 2 H, —C(O)O(C 1 -C 4 )alkyl and —P(O)R f R g ; 
         cyclopropyl, optionally substituted with 1 —CO 2 H; 
         C(O)NR a R b  wherein R a  and R b  are independently selected from H and (C 1 -C 4 )alkyl, wherein the (C 1 -C 4 )alkyl is optionally substituted with 1-3 groups independently selected from hydroxy, —CO 2 H, —C(O)O(C 1 -C 4 )alkyl, —P(O)R f R g , NR c R d  and N + R c R d R e ; 
         (C 1 -C 6 )alkoxy, optionally substituted with 1-3 substituents independently selected from halo, hydroxy, —CO 2 H, (C 3 -C 6 )cycloalkyl, —C(O)NH 2  and pyrrolidinyl; 
         (C 3 -C 6 )cycloalkoxy, optionally substituted with 1-3 substituents independently selected from halo, hydroxy, and —CO 2 H; 
         —NR a R b  wherein R a  and R b  are independently selected from H and (C 1 -C 4 )alkyl, wherein the (C 1 -C 4 )alkyl is optionally substituted with 1-3 groups independently selected from oxo and —CO 2 H; 
         —SR a  wherein R a  is selected from H and (C 1 -C 4 )alkyl; 
         —CO 2 H; —C(NOH)NH 2 ; cyano; —C(O)O(C 1 -C 4 )alkyl; —C(O)CO 2 H; —P(O)R f R g ; —OP(O)R f R g ; halo; hydroxy; nitro; —NHSO 2 (C 1 -C 2 )alkyl; —SO 3 H; —SO 2 (C 1 -C 2 )alkyl; —SO 2 NR c R d ; —SO 2 NHC(O)(C 1 -C 2 )alkyl; and —B(OH) 2 ;
 and 
 b) heteroaryl, optionally substituted with 1-2 groups independently selected from: 
 
         (C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxy, oxo, —CO 2 H, —P(O)R f R g , and —OP(O)R f R g ;
 wherein in each occurrence: 
 R c , R d  and R e  are independently selected from H and (C 1 -C 2 )alkyl; and 
 R f  and R g  are independently selected from hydroxy, (C 1 -C 2 )alkyl and (C 1 -C 2 )alkoxy. 
 
       
     
     
         17 . The method according to  claim 16 , wherein R1 and R2 have (R) stereochemistry. 
     
     
         18 . The method according to  claim 17 , wherein R3 is said optionally substituted phenyl. 
     
     
         19 . The method according to  claim 18 , wherein R3 is phenyl substituted with 1-3 groups selected from: —OCH 3 , —OC 2 H 5 , —OC 3 H 7 , —OCH(CH 3 ) 2 , —OCF 3 , —OCHF 2 , —OCH 2 CF 3 , —OCH 2 CHF 2 , —OC 2 H 4 -pyrrolidine, —OCH 2 CO 2 H, —OCH 2 C(O)NH 2 , —CO 2 H, —CH 3 , cyclopropane-1-carboxylic acid, —CH 2 CO 2 H, —C(CH 3 ) 2 CO 2 H, —CH(CH 3 )CO 2 H, —CF 2 CO 2 H, —CH 2 C(O)NHCH(CO 2 H)(CH 2 CO 2 H), —CH 2 P(O)(OH) 2 , —CH 2 N(CH 3 )(CH 2 CO 2 H), —CH 2 NHCH 2 P(O)(OH) 2 , —C(NH 2 )(NOH), cyano, nitro, hydroxy, —SO 2 NH 2 , —SO 2 N(CH 3 ) 2 , —SO 2 NH(CH 3 ), —SO 2 CH 3 , —SO 2 NHC(O)C 2 H 5 , —SCH 3 , —SC 2 H 5 , —C(O)OCH 3 , —C(O)OC(CH 3 ) 3 , —C(O)NHCH 3 , —C(O)NH(C 2 H 4 NH 2 ), —C(O)NHC 2 H 4 N+(CH 3 ) 3 , —C(O)NHCH(CO 2 H)(CH 2 CO 2 H), —C(O)NHCH(CO 2 H)(C 2 H 4 CO 2 H), —C(O)NHCH 2 CO 2 H, —C(O)N(CH 2 CO 2 H) 2 , —C(O)NHCH 2 P(O)(OH) 2 , —C(O)NHC(CH 2 OH) 3 , fluoro, —NH 2 , —N(CH 3 ) 2 , —P(O)(CH 3 )(OC 2 H 5 ), —P(O)(OCH 3 ) 2 , —P(O)(CH 3 )(OH), —P(O)(OH)(OCH 3 ), and —P(O)(OH) 2 . 
     
     
         20 . The method according to  claim 19 , wherein R3 is phenyl substituted with 1-3 groups selected from: —OC 2 H 5 , hydroxy, —CO 2 H, —OCH 2 CO 2 H, —P(O)(OH) 2 , —C(O)NHCH(CO 2 H)(CH 2 CO 2 H) and —C(O)NHCH 2 P(O)(OH) 2 . 
     
     
         21 . The method according to  claim 20 , wherein: R1 is ethyl and R2 is n-pentyl. 
     
     
         22 . The method according to  claim 16 , wherein: R1 is methyl, ethyl or —CH 2 OH. 
     
     
         23 . The method according to  claim 16 , wherein: R1 is ethyl. 
     
     
         24 . The method according to  claim 1 , wherein the compound of Formula (I) is selected from the group consisting of:
 2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl) carbamoyl)furan-2-yl)benzoic acid,   (R)—N-((3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanamido)methyl)-5-phenylfuran-2-carboxamide,   (R)—N-((2-((N-hydroxyformamido)methyl)phenylpentanamido)methyl)-5-phenylfuran-2-carboxamide,   (R)—N-((2-((N-hydroxyformamido)methyl)-4-phenylbutanamido)methyl)-5-phenylfuran-2-carboxamide,   (R)—N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-phenylfuran-2-carboxamide,   (R)—N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(2-methoxyphenyl)furan-2-carboxamide,   (R)—N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(3-methoxyphenyl)furan-2-carboxamide,   (R)-5-(3-cyanophenyl)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)furan-2-carboxamide,   (R)—N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(2-hydroxyphenyl)furan-2-carboxamide,   (R)—N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(5-methoxypyridin-3-yl)furan-2-carboxamide,   (R)-5-(4-cyanophenyl)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)furan-2-carboxamide,   (R)—N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(3-sulfamoylphenyl)furan-2-carboxamide,   (R)—N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(3-(trifluoromethoxy)phenyl)furan-2-carboxamide,   (R)-5-(3-ethoxyphenyl)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)furan-2-carboxamide,   (R)—N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(6-methoxypyridin-2-yl)furan-2-carboxamide,   (R)-methyl 3-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoate,   (R)-5-(4-fluoro-3-methoxyphenyl)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)furan-2-carboxamide,   (R)—N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(4-methoxypyridin-2-yl)furan-2-carboxamide,   (R)—N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(3-(methylcarbamoyl)phenyl)furan-2-carboxamide,   (R)—N-((2-((N-hydroxyformamido)methyl)-4-phenylbutanamido)methyl)-5-(3-(methylsulfonyl)phenyl)furan-2-carboxamide,   (R)-5-(3-(N,N-dimethylsulfamoyl)phenyl)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)furan-2-carboxamide,   (R)—N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(3-(N-methylsulfamoyl)phenyl)furan-2-carboxamide,   (R)—N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(3-(2,2,2-trifluoroethoxy)phenyl)furan-2-carboxamide,   N—(((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)-5-phenylfuran-2-carboxamide,   (R)—N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(3-isopropoxyphenyl)furan-2-carboxamide,   (R)-methyl 3-ethoxy-5-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoate,   (R)-5-(3-(dimethylamino)phenyl)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)furan-2-carboxamide,   (R)—N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(3-(N-propionylsulfamoyl)phenyl)furan-2-carboxamide,   (R)-3-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)-5-methoxybenzoic acid,   (R)-3-ethoxy-5-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid,   ethyl (3-(5-((((R)-2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)(methyl)phosphinate,   N—(((R)-2-((S)-2-hydroxy-1-(N-hydroxyfonnamido)ethyl)heptanamido)methyl)-5-phenylfuran-2-carboxamide,   (R)-5-(3-((2-aminoethyl)carbamoyl)-5-methoxyphenyl)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)furan-2-carboxamide,   (R)-5-(3-((2-aminoethyl)carbamoyl)-5-ethoxyphenyl)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)furan-2-carboxamide,   (R)-5-(3-(difluoromethoxy)phenyl)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)furan-2-carboxamide,   (R)-dimethyl (3-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)phosphonate,   (R)-5-(1,1-dioxido-2,3-dihydrobenzo[d]isothiazol-6-yl)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)furan-2-carboxamide,   (R)—N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(3-(2-(pyrrolidin-1-yl)ethoxy)phenyl)furan-2-carboxamide,   3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl) furan-2-yl)benzoic acid,   5-(3-((2-aminoethyl)carbamoyl)-5-ethoxyphenyl)-N—(((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)furan-2-carboxamide,   2-(2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)acetic acid,   2-(4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)acetic acid,   2-(4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)-2-methylpropanoic acid,   1-(4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)cyclopropanecarboxylic acid,   (S)-5-(tert-butoxy)-4-(3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl) heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)-5-oxopentanoic acid,   5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)nicotinic acid,   (S)-4-(tert-butoxy)-3-(3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)-4-oxobutanoic acid,   (S)-dimethyl 2-(3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl) carbamoyl)furan-2-yl)benzamido)pentanedioate,   2-(3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)-2,2-difluoroacetic acid,   dimethyl (3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)phosphonate,   (R)-methyl 2-fluoro-5-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl) furan-2-yl)benzoate,   (R)-5-(3,5-dimethoxyphenyl)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)furan-2-carboxamide,   (R)-5-(2,5-dimethoxyphenyl)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)furan-2-carboxamide,   (R)-5-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)-2-methylbenzoic acid,   (R)-3-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)-2-methoxybenzoic acid,   (R)-5-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)-2-methoxybenzoic acid,   (R)-methyl 2-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoate,   (R)-methyl 4-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoate,   (R)-2-fluoro-3-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid,   (R)-2-(3-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)acetic acid,   (R)-3-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)-2-methylbenzoic acid,   (R)-2-hydroxy-5-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid,   (R)-tert-butyl 3-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoate,   (R)-2-amino-5-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid,   2-(3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)-N,N,N-trimethylethanaminium hydroxide,   5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)-2-methoxybenzoic acid,   2-(3-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)-2-methylpropanoic acid,   5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)-2-methylbenzoic acid,   N—(((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)-5-(3-propoxyphenyl)furan-2-carboxamide,   2-(2-fluoro-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)acetic acid,   4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid,   2-(3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)acetic acid,   5-(3-ethoxy-5-hydroxyphenyl)-N—(((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)furan-2-carboxamide,   (S)-2-(2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl) carbamoyl)furan-2-yl)benzamido)succinic acid,   (S)-2-(2-(2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)acetamido)succinic acid,   2-(3-(5-((((R)-2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)propanoic acid,   (S)-2-(3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid,   (R)-2,6-difluoro-3-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid,   3-ethoxy-5-(5-(((3-(N-hydroxyformamido)propanamido)methyl)carbamoyl)furan-2-yl)benzoic acid,   1-(3-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)cyclopropanecarboxylic acid,   5-ethoxy-2-hydroxy-3-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid,   3-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)-5-propoxybenzoic acid,   (S)-2-(3-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid,   (R)-2-(3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid,   2-(3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)acetic acid,   2,2′-((2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoyl)azanediyl)diacetic acid,   2,2′-((3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoyl)azanediyl)diacetic acid,   5-(3-((1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl)carbamoyl)-5-ethoxyphenyl)-N—(((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)furan-2-carboxamide,   (R)-3-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid,   (R)-2-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid,   (R)-2-fluoro-5-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid,   (R)-4-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid,   (S)-2-(3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)pentanedioic acid,   (3-(5-((((R)-2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)(methyl)phosphinic acid,   methyl hydrogen (3-(5-((((R)-2-((N-hydroxyformamido)methyl)heptanamido)methyl) carbamoyl)furan-2-yl)phenyl)phosphonate,   (3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl) furan-2-yl)phenyl)phosphonic acid,   (3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl) carbamoyl)tetrahydrofuran-2-yl)phenyl)phosphonic acid,   (2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl) furan-2-yl)phenyl)phosphonic acid,   (3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzyl)phosphonic acid,   ((3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)methyl)phosphonic acid,   methyl hydrogen (3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)phosphonate,   (R)-5-(3-(2,2-difluoroethoxy)phenyl)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)furan-2-carboxamide,   (R)-5-(3-(ethylthio)phenyl)-N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl) furan-2-carboxamide,   (R)—N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(3-(methylthio)phenyl)furan-2-carboxamide,   (R)—N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(3-nitrophenyl)furan-2-carboxamide,   (R)—N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(1-methyl-1H-indazol-6-yl)furan-2-carboxamide,   (R)—N-((2-((N-hydroxyformamido)methyl)heptanamido)methyl)-5-(2-methyl-2H-indazol-6-yl)furan-2-carboxamide,   (R)-(3-(5-(((2-((N-hydroxyformamido)methyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)phosphonic acid,   5-(3-((Z)—N′-hydroxycarbamimidoyl)phenyl)-N—(((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)furan-2-carboxamide, and   N—(((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)-5-phenyltetrahydrofuran-2-carboxamide.   
     
     
         25 . The method according to  claim 1 , wherein the compound of Formula (I) is selected from the group consisting of:
 (3-ethoxy-2-fluoro-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid,   3-hydroxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid,   3-(carboxymethoxy)-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid,   2-(carboxymethyl)-4-(5-((((R)-2-((R)-1-(N-hydroxyfonnamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid,   5-ethoxy-2-hydroxy-3-(5-((((2R,3R)-3-(N-hydroxyformamido)-2-phenethylpentanamido)methyl)carbamoyl)furan-2-yl)benzoic acid,   (S)-2-(2-ethoxy-4-(5-((((2R,3R)-3-(N-hydroxyformamido)-2-(2-(naphthalen-2-yl)ethyl)pentanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid,   5-(carboxymethoxy)-3-(5-((((2R,3R)-2-(2,4-difluorophenethyl)-3-(N-hydroxyfonnamido)pentanamido)methyl)carbamoyl)furan-2-yl)-2-hydroxybenzoic acid,   (S)-2-(4-(5-((((R)-2-((R)-1-(N-hydroxyfonnamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid,   (S)-2-(4-(5-((((R)-2-((R)-1-(N-hydroxyfonnamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)-2-methylbenzamido)succinic acid,   5-(carboxymethoxy)-2-hydroxy-3-(5-((((R)-2-((R)-1-(N-hydroxyfonnamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid,   2,2′-((3-(5-((((2R,3R)-2-(2,4-difluorophenethyl)-3-(N-hydroxyfonnamido)pentanamido)methyl)carbamoyl)furan-2-yl)-5-ethoxybenzoyl)azanediyl)diacetic acid,   (S)-2-(4-(5-((((2R,3R)-2-(2,4-difluorophenethyl)-3-(N-hydroxyformamido)pentanamido)methyl)carbamoyl)furan-2-yl)-2-ethoxybenzamido)succinic acid,   2,2′-((2-ethoxy-4-(5-((((2R,3R)-3-(N-hydroxyformamido)-2-phenethylpentanamido)methyl)carbamoyl)furan-2-yl)benzoyl)azanediyl)diacetic acid,   (S)-2-(3-(carboxymethoxy)-5-(5-((((R)-2-((R)-1-(N-hydroxyfonnamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid,   (S)-2-(2-(carboxymethoxy)-4-(5-((((R)-2-((R)-1-(N-hydroxyfonnamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid,   (S)-2-(2-ethoxy-4-(5-((((2R,3R)-3-(N-hydroxyformamido)-2-phenethylpentanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid,   2-ethoxy-6-hydroxy-4-(5-((((R)-2-((R)-1-(N-hydroxyfonnamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid,   4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phthalic acid,   2-((3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyfonnamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzyl)(methyl)amino)acetic acid,   3-(2-amino-2-oxoethoxy)-5-(5-((((R)-2-((R)-1-(N-hydroxyfonnamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid,   (R)-2-(2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyfonnamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid,   ((R)-2-(4-(5-((((R)-2-((R)-1-(N-hydroxyfonnamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid,   (S)-2-(4-(5-((((R)-2-((R)-1-(N-hydroxyfonnamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)pentanedioic acid,   (S)-2-(2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyfonnamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)pentanedioic acid,   2,2′-((4-(5-((((R)-2-((R)-1-(N-hydroxyfonnamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoyl)azanediyl)diacetic acid,   (((3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyfonnamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzyl)amino)methyl)phosphonic acid,   (3-hydroxy-5-(5-((((R)-2-((R)-1-(N-hydroxyfonnamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)phosphonic acid,   ((2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)methyl)phosphonic acid,   (3-ethoxy-5-(5-((((2R,3R)-3-(N-hydroxyformamido)-2-phenethylpentanamido)methyl)carbamoyl)furan-2-yl)phenyl)phosphonic acid,   (3-ethoxy-5-(5-((((2R,3R)-3-(N-hydroxyformamido)-2-(2-(naphthalen-2-yl)ethyl)pentanamido)methyl)carbamoyl)furan-2-yl)phenyl)phosphonic acid,   ((2-hydroxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)methyl)phosphonic acid,   ((4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)methyl)phosphonic acid,   ((4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)-2-methylbenzamido)methyl)phosphonic acid,   2-(3-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)-5-phosphonophenoxy)acetic acid, and   2-hydroxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid.   
     
     
         26 . The method according to  claim 1 , wherein the compound of Formula (I) is selected from the group consisting of:
 2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl) carbamoyl)furan-2-yl)benzoic acid,   3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl) furan-2-yl)benzoic acid,   (S)-2-(2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl) carbamoyl)furan-2-yl)benzamido)succinic acid,   (S)-2-(3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid,   5-ethoxy-2-hydroxy-3-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid,   (3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl) furan-2-yl)phenyl)phosphonic acid,   (2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl) furan-2-yl)phenyl)phosphonic acid,   3-(carboxymethoxy)-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzoic acid,   (S)-2-(4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid,   (S)-2-(2-(carboxymethoxy)-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid,   4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phthalic acid,   (3-hydroxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)phenyl)phosphonic acid,   ((2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)methyl)phosphonic acid, and   (3-ethoxy-5-(5-((((2R,3R)-3-(N-hydroxyformamido)-2-phenethylpentanamido)methyl)carbamoyl)furan-2-yl)phenyl)phosphonic acid.   
     
     
         27 . The method according to  claim 1 , wherein the compound of Formula (I) is (3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl) furan-2-yl)phenyl)phosphonic acid of formula: 
       
         
           
           
               
               
           
         
       
     
     
         28 . The method according to  claim 1 , wherein the pharmaceutically acceptable salt of the compound of Formula (I) is a meglumine salt, Tris salt, or calcium salt of (3-ethoxy-5-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl) furan-2-yl)phenyl)phosphonic acid. 
     
     
         29 . The method according to  claim 1 , wherein the compound of Formula (I) is (S)-2-(2-ethoxy-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl) carbamoyl)furan-2-yl) 1 benzamido)succinic acid of formula: 
       
         
           
           
               
               
           
         
       
     
     
         30 . The method according to  claim 1 , wherein the compound of Formula (I) is (S)-2-(2-(carboxymethoxy)-4-(5-((((R)-2-((R)-1-(N-hydroxyformamido)propyl)heptanamido)methyl)carbamoyl)furan-2-yl)benzamido)succinic acid of formula: 
       
         
           
           
               
               
           
         
       
     
     
         31 . The method according to  claim 1 , wherein the disease associated with BMP1, TLL1 and/or TLL2 activity is selected from diseases associated with pathological fibrotic conditions of the heart, lung, kidney, liver, eye, skin, skeletal muscle, vasculature, or nervous system. 
     
     
         32 . The method according to  claim 31 , wherein the disease is selected from: myocardial infarction, heart failure, cardiac arrhythmia, hypertrophic cardiomyopathy, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, diabetic nephropathy, post-acute kidney injury, chronic kidney disease, delayed graft function post-transplantation, liver cirrhosis, non-alcoholic steatohepatitis, glaucoma, corneal scarring, muscular dystrophy, keloids, wound healing, adhesions, hypertrophic scarring, scarring, e.g., associated with burns, surgery or other trauma, stroke, collagen vascular diseases, systemic lupus erythematosus, rheumatoid arthritis, scleroderma, spinal cord injury, and multiple sclerosis. 
     
     
         33 . The method according to  claim 1 , wherein the disease associated with BMP1, TLL1 and/or TLL2 activity is selected from muscular diseases characterized by reduced muscle function and/or mass. 
     
     
         34 . The method according to  claim 33 , wherein the muscular disease is selected from: muscular dystrophy, sarcopenia, and cachexia associated with, e.g., heart failure, CKD, COPD, cancer, or old age. 
     
     
         35 . The method according to  claim 1 , comprising administering to said human a therapeutically effective amount of a) the compound of Formula (I) or a pharmaceutically acceptable salt thereof; and b) a combination partner.